Offensperger W B, Offensperger S, Keppler-Hafkemeyer A, Hafkemeyer P, Blum H E
Department of Medicine II, University of Freiburg, Germany.
Antivir Ther. 1996 Aug;1(3):141-6.
Chronic hepatitis B virus (HBV) infection is a major health problem worldwide. Antiviral strategies available at present, including interferon-alpha, have only limited efficacy, leading us to analyse the antiviral effects of penciclovir and famciclovir in the duck hepatitis B virus (DHBV) model of HBV infection in vitro and in vivo. In DHBV-infected duck hepatocytes, penciclovir effectively inhibited viral replication, with a concentration giving half-maximal inhibition of 0.25 microM. Furthermore, in vivo, penciclovir and its orally administered prodrug famciclovir strongly inhibited DHBV replication. These data demonstrate that penciclovir and famciclovir both have strong antiviral activities, and suggest that these agents might be useful for treating HBV infection in humans.
慢性乙型肝炎病毒(HBV)感染是全球主要的健康问题。目前可用的抗病毒策略,包括α干扰素,疗效有限,这促使我们在体外和体内的鸭乙型肝炎病毒(DHBV)感染模型中分析喷昔洛韦和泛昔洛韦的抗病毒作用。在感染DHBV的鸭肝细胞中,喷昔洛韦有效抑制病毒复制,半数最大抑制浓度为0.25微摩尔。此外,在体内,喷昔洛韦及其口服前体药物泛昔洛韦强烈抑制DHBV复制。这些数据表明,喷昔洛韦和泛昔洛韦均具有强大的抗病毒活性,并提示这些药物可能对治疗人类HBV感染有用。